The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Tafinlar [package insert]. Research Triangle Park, NC: GlaxoSmithKline 2013.
2.
FalchookGSLongGVKurzrockR. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase I dose-escalation trial. Lancet.2012;379(9829):1893–1901.
3.
LongGVTrefzerUDaviesMA. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol.2012;13(11):1087–1095.
4.
FlahertyKTInfanteJRDaudA. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med.2012;367(18):1694–1703.
5.
HauschildAGrobJJDemidovLV. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet.2012;380(9839):358–365.
6.
Mekinist [package insert]. Research Triangle Park, NC: GlaxoSmithKline 2013.
7.
FalchookGSLewisKDInfanteJR. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. Lancet Oncol.2012;13(8):782–789.
8.
InfanteJRFecherLAFalchookGS. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol.2012;13(8):773–781.
9.
FlahertyKTRobertCHerseyP. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med.2012;367(2):107–114.
10.
KimKBKeffordRPavlickAC. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol.2013;31(4):482–489.
